TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06753656

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Surgery
Description: Open surgery technique: A longitudinal incision is made over the lateral malleolus, followed by sharp dissection down to the bone. The fracture is reduced under direct visualization and fixed with a plate and screws.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Surgery
Description: Closed surgery technique: A 2-3 cm longitudinal incision is made distal to the lateral malleolus to allow for plate placement. A periosteal elevator is used to create a pathway for the plate. The fracture is reduced in a closed manner using reduction clamps, and the plate position is confirmed fluoroscopically. A second longitudinal incision is made proximal to the fracture, and the plate is temporarily fixed with Kirschner wires. The plate is then used as an external guide, with screws placed through mini-incisions. The fracture is fixed with the plate-screw system in a minimally invasive manner.
Study: NCT06753877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: holistic rehabilitation
Description: Holistic rehabilitation service All participants in the study were cared for in the inpatient unit. The same physician and nurses followed the participants for 1 month. The participants were regularly taking their medication and had no co-morbidities. All participants stayed in double rooms and all stayed with their caregivers. The assessments were carried out within the first 3 days of admission to the inpatient unit. The second assessments were repeated by the same professional. Rehabilitation interventions were provided by different therapists. Participants were given standard physiotherapy services (electrotherapy, exercise, gait training, hydrotherapy, respiratory therapy) and standard occupational therapy services. Occupational therapy interventions were provided by the researchers. Physiotherapy services were provided by physiotherapists working full-time in the hospital. Physiotherapy was provided 5 days a week and occupational therapy was provided 3 days a week.
Study: NCT06758765

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: ESPB was applied to the patients in a sitting position. A high-frequency linear probe was used. Under sterile conditions, the USG probe was placed longitudinally approximately 2 cm lateral to the T4 spinous process. Skin, subcutaneous fat tissue, m. trapezius, rhomboid muscles, erector group muscles, transverse process, intercostal muscles, pleura and lung movements were visualized from superficial to deep structures. 1 ml of 2% lidocaine was injected into the estimated needle entry area. Then, with the block needle the m. trapezius, mm. rhomboidei and erector spinae muscles were passed in order with the in-plane method and the needle was brought into contact with the transverse process. Fascial separation was confirmed with 1-2 ml of saline solution and the block was performed by injecting 20 ml of 0.375% bupivacaine. The distribution of the drug was confirmed by observing it with USG.
Study: NCT04633473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIB-Time Web-Application Tool
Description: Parents used the dual-language SIBTime app to watch video stories about common sibling experiences, respond to question prompts, track connection routines, and listen to guided Acceptance and Commitment Therapy (ACT) exercises for parents. During the 4-week intervention period, parents used the app at their convenience.
Study: NCT05213468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PainDrainerTM
Description: Self management digital tool for chronic pain
Study: NCT05006664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adcetris 50 MG Injection
Description: Treatment by study drug Brentuximab Vedotin (Adcetris) in combination with CHEP.
Study: NCT06758765

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectoral Nerve Block
Description: The PECSI and PECSII blocks were applied concurrently.~In patients who will undergo PECS II, sterile conditions were prepared with the arm on the side to be operated on in the supine position and 90 degrees of abduction. The lateral and pectoral branches of the thoracoacromial artery were visualized between the PM and Pm muscles at the level of the 4th rib under USG guidance. The blocking needle was directed between the PM and Pm muscles for PECS I, 1-2 ml of saline was injected to verify fascial spread, and 10 ml of 0.375% bupivacaine was applied. Afterwards, fascial spread was confirmed by injecting 1-2 ml of saline between the pectoralis minor muscle and the serratur anterior muscle, and PECS II was performed by injecting 10 ml of 0.375% concentration bupivacaine. The distribution of the drug was confirmed by observing it with USG.
Study: NCT05006664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endoxan
Description: Treatment by study drug Cyclophosphamide (Endoxan) in combination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Treatment by study drug Doxorubicin in combination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Treatment by study drug Etoposide in combination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone tablet
Description: Treatment by study drug Prednisone in combination.
Study: NCT05467657

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: It will be applyed a magnetic field over the Somatosensory cortex of the patient that pretends to hiperexcite the membrans of the neurons inthis area to enhance motor learning
Study: NCT06759090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronomic capecitabine
Description: Metronomic capecitabine: 650 mg/m2, twice daily, to be swallowed with water within 30 minutes after a meal;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab: a PD-1 inhibitor, 200 mg, intravenous injection once every 2 weeks;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate Tablets
Description: Apatinib mesylate: a small molecule of tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) , 250mg, once daily, to be swallowed with water within 30 minutes after a meal.
Study: NCT06759051

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: The stimulation pattern for the true intervention was that the current level ramped up from 0 to 2 mA for the first 10 seconds of stimulation, then maintained at 2 mA for 19 minutes and 40 seconds, and then ramped down from 2 mA to 0 mA for the last 10 seconds, all over a 20-minute period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: The stimulation pattern for the true intervention was that the current level ramped up from 0 to 2 mA for the first 10 seconds of stimulation, then maintained at 2 mA for 19 minutes and 40 seconds, and then ramped down from 2 mA to 0 mA for the last 10 seconds, all over a 20-minute period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: The stimulation pattern for the true intervention was that the current level ramped up from 0 to 2 mA for the first 10 seconds of stimulation, then maintained at 2 mA for 19 minutes and 40 seconds, and then ramped down from 2 mA to 0 mA for the last 10 seconds, all over a 20-minute period.
Study: NCT05467657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation
Description: It will be applyed a magnetic field over the Somatosensory cortex of the patient that pretends to hiperexcite the membrans of the neurons inthis area to enhance motor learning
Study: NCT05059730

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zero Degrees Cold Environment
Description: Participants will be exposed to zero degrees celsius environment.
Study: NCT06759051

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: In contrast to the active intervention, the sham intervention consisted of a current ramp from 0mA to 2mA for the first 20 seconds of stimulus onset, followed by a ramp down to 0mA. the current was maintained at 0mA for 19 minutes and 20 seconds, and then the current was ramped from 0mA to 2mA for the last 20 seconds, followed by a ramp down to 0mA. The entire procedure lasted the same as the active intervention, which lasted for 20 minutes.
Study: NCT04627714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity
Description: Intervention consists in 1h30/week of adapted fencing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity
Description: Intervention consists in 1h30/week of adapted fencing
Study: NCT06759051

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: In contrast to the active intervention, the sham intervention consisted of a current ramp from 0mA to 2mA for the first 20 seconds of stimulus onset, followed by a ramp down to 0mA. the current was maintained at 0mA for 19 minutes and 20 seconds, and then the current was ramped from 0mA to 2mA for the last 20 seconds, followed by a ramp down to 0mA. The entire procedure lasted the same as the active intervention, which lasted for 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: In contrast to the active intervention, the sham intervention consisted of a current ramp from 0mA to 2mA for the first 20 seconds of stimulus onset, followed by a ramp down to 0mA. the current was maintained at 0mA for 19 minutes and 20 seconds, and then the current was ramped from 0mA to 2mA for the last 20 seconds, followed by a ramp down to 0mA. The entire procedure lasted the same as the active intervention, which lasted for 20 minutes.
Study: NCT06760039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CMOP Regimen
Description: Rituximab intravenous drip, Cyclophosphamide intravenous drip, Liposomal Mitoxantrone intravenous drip, Vincristine intravenous drip, Prednisone orally
Study: NCT05059730

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zero Degrees Cold Environment
Description: Participants will be exposed to zero degrees celsius environment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zero Degrees Cold Environment
Description: Participants will be exposed to zero degrees celsius environment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eight Degrees Cold Environment
Description: Participants will be exposed to eight degrees celsius environment.
Study: NCT06760039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-CHOP Regimen
Description: Rituximab intravenous drip, Cyclophosphamide intravenous drip, Doxorubicinin intravenous drip, Vincristine intravenous drip, Prednisone orally
Study: NCT05059730

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ten Degrees Cold Environment
Description: Participants will be exposed to Ten degrees celsius environment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 40 degrees Hot Environment
Description: Participants will be exposed to 40 degrees celsius hot environment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 40 degrees Hot Environment
Description: Participants will be exposed to 40 degrees celsius hot environment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 40 degrees Hot Environment
Description: Participants will be exposed to 40 degrees celsius hot environment.
Study: NCT05262803

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CYP2C19*2/*3
Description: * Non-carriers of CYP2C19\*2/\*3 loss-of-function alleles: DAPT with clopidogrel and ASA~* Carriers of CYP2C19\*2/\*3 loss-of-function alleles: DAPT with prasugrel (or ticagrelor) and ASA

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CYP2C19*2/*3
Description: * Non-carriers of CYP2C19\*2/\*3 loss-of-function alleles: DAPT with clopidogrel and ASA~* Carriers of CYP2C19\*2/\*3 loss-of-function alleles: DAPT with prasugrel (or ticagrelor) and ASA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shorter DAPT duration
Description: Duration of DAPT is shortened to 3 months
Study: NCT04430426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled Diet
Description: Participants will consume a controlled low oxalate diet for five days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glycolate Administration
Description: Participants will come to the UAB Clinical Research Unit (CRU) and be administered a glycolate load via intravenous (IV) catheter.
Study: NCT06759441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reframe-It+
Description: Reframe-IT+ is an individual intervention based on cognitive behavioral therapy, with a problem-solving and help-seeking approach, which is carried out at the Educational Establishment with a trained psychologist. It consists of 13 weekly sessions of 25 minutes each, of which 5 sessions have a face-to-face component and 8 sessions have a face-to-face-digital component where students use a computer always in the company of a psychologist facilitating the program.
Study: NCT06758908

Intervention type: DEVICE
Intervention: Antibiotic
Description: SALI
Study: NCT06759194

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium Laser Enucleation of the Prostate
Description: Enucleation of the prostate gland using holmium laser energy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar Enucleation of the Prostate
Description: Enucleation of the prostate gland using bipolar energy
Study: NCT06759454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glutaraldehyde-Based Desensetizing Agent
Description: A glutaraldehyde-based desensitizing agent applied to the cervical area of affected teeth using a micro-brush, left undisturbed for 30 seconds, and air-dried. Both interventions aim to reduce pain associated with dentinal hypersensitivity by either occluding dentinal tubules or reducing nerve excitability

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: Low-level laser therapy (LLLT) using a diode laser set to a low power level (e.g., 100 mW, continuous wave mode). Each affected tooth will be treated for three minutes, targeting apical, cervical, and middle points
Study: NCT05905913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANT3310
Description: ANT3310 will be infused over 3 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ANT3310-placebo
Description: ANT3310-placebo will be infused over 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANT3310
Description: ANT3310 will be infused over 3 hours every 8 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ANT3310-placebo
Description: ANT3310-placebo will be infused over 3 hours every 8 hours
Study: NCT06760351

Intervention type: DRUG
Intervention: TCM Herbal Therapy
Description: Administration of customized herbal formulations for the TCM group, targeting qi and blood regulation. Pulse diagnosis parameters were evaluated monthly to guide treatment adjustments.

Intervention type: DRUG
Intervention: Standard Western Medicine Treatment
Description: Administration of standard Western medical care, including blood transfusions and erythropoiesis-stimulating agents, focusing on hemoglobin restoration and anemia management.
Study: NCT06759805

Intervention type: OTHER
Group type: OTHER
Intervention: eCardiacRehab
Description: Interdisciplinary supervised home-based digital secondary prevention programme (12-week programme) based on the European Society of Cardiology guidelines for cardiac rehabilitation for patients after percutaneous coronary intervention.
Study: NCT06760416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing Education
Description: 5 modules of online foot care training, motivational messages and informative videos for the patient who was given a foot care kit
Study: NCT06758869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants will consume the Base DGA diet with a standardized non-pulse product snack.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Chickpeas
Description: Participants will consume an adjusted DGA diet with a standardized whole chickpea snack.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Puréed Chickpeas
Description: Participants will consume an adjusted DGA diet with a standardized puréed chickpea snack.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% Chickpea Flour Product
Description: Participants will consume an adjusted DGA diet with a standardized 100% chickpea flour product snack.
Study: NCT06758570

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pectin dosages
Description: 15 individuals were provided with increasing doses of pectin: 5g for 2 weeks 10g for 2 weeks 15 for 2 weeks
Study: NCT06758583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapiglutide 7.5 mg
Description: Single dose administration of 7.5 mg dapiglutide administered s.c. with two drug product concentrations, 10 mg/mL and 25 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapiglutide 7.5 mg
Description: Single dose administration of 7.5 mg dapiglutide administered s.c. with two drug product concentrations, 10 mg/mL and 25 mg/mL.
Study: NCT05905913

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ANT3310-placebo
Description: ANT3310-placebo will be infused over 3 hours as a single dose as part of the drug drug interaction study, then every 8 hours as part of the repeat doses study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANT3310
Description: ANT3310 will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: Meropenem will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Meropenem-placebo
Description: Meropenem-placebo will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.
Study: NCT05183412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Sedakit Oncomfort VR glasses (30-minutes Aqua program)
Description: During placement of ultrasound-guided regional nerve block (axillary or distal peripheral) and hand surgery, patients are subjected to a 30-minutes VR program (Oncomfort SA, Wavre, Belgium) 'Aqua' via a head-mounted display and headphone. The patients watch a VR underwater view of the ocean while listening to speeches to induce relaxation and meditation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided regional nerve block and hand surgery without VR glasses
Description: During placement of ultrasound-guided regional nerve block (axillary or distal peripheral) and hand surgery, patients are NOT subjected to a 30-minutes VR program (Oncomfort SA, Wavre, Belgium) 'Aqua' via a head-mounted display and headphone.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided regional nerve block and hand surgery with VR glasses
Description: Ultrasound-guided regional nerve block and hand surgery with VR glasses
Study: NCT04893434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Each patient will undergo 3 Gadavist injections. The intravenous injection of the GBCA Gadobutrol (Gadavist, Bayer Healthcare) at 0.1 mL/kg body weight (0.1 mmol/kg), administered as a bolus at a flow rate of approximately 2 mL/s. Each volunteer will undergo 1 and each patient 2 research Gadobutrol injections (the 3 injections mentioned in the protocol for patients is to account for the fact they will have had 1 injection as part of their standard of care, but the study only includes 2 research injections).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: All subjects will be imaged on the same 3T MRI scanner (GE Healthcare, USA) at MSK for all examinations. For SA1, subjects will undergo a single research DCE-MRI exam. Patients in SA2 will undergo a standard of care pelvic MRI at baseline (which includes DCE-standard) in accordance with standard clinical operating procedures at MSK.
Study: NCT06484569

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The content of ergonomics training will include the definition of ergonomics, ergonomic positions and arrangements. Postural arrangements will be explained to patients individually and supported by a brochure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: The content of ergonomics training will include the definition of ergonomics, ergonomic positions and arrangements. Postural arrangements will be explained to patients individually and supported by a brochure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and cranio sacral therapy
Description: Posture exercises Stretching exercises Strengthening Exercises In addition, deep tissue massage will be applied to increase blood circulation and cranio-sacral therapy will be applied to increase cerebrospinal fluid circulation.
Study: NCT06200428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sleep support pillow
Description: A sleep support pillow will be used in this study.
Study: NCT04815694

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT Dose escalation in LARC patients with an Early Regression Index > 13.1 at second week on nCRT
Description: The initial radiotherapy treatment will consist in delivering 55 Gy in 25 fractions on GTV plus the corresponding mesorectum of 45Gy in 25 fractions on the whole pelvis. Chemotherapy with 5-fluorouracil (5-FU) or oral capecitabine will be administered continuously. A 0.35 Tesla Magnetic resonance image will be acquired at simulation and every day during MRgRT. At fraction 10, ERI will be calculated. If ERI will be inferior than 13.1 the patient will continue the original treatment. If ERI will be higher than 13.1 the treatment plan will be reoptimized considering the residual tumor at fraction 10 as new therapy volume, where the dose will be intensified to reach 60.1 Gy.